

DOCKET NO.: BDT-0003

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Brian Hashemi

Application No.: 10/817,644

Filing Date: April 2, 2004

For: CELLULAR ANALYSIS

Confirmation No.: 2841

Group Art Unit: 1641

Examiner: Not Yet Assigned

DATE OF DEPOSIT: August 16, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

*Elizabeth A. McLoud*  
TYPED NAME Elizabeth A. McLoud

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;

or

☐ The fee of **\$180.00** as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of **\$180.00** as set forth in § 1.17(p).

- ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- ☒ Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).


## EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☒ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
- ☒ Copies of references **1-23** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. **10/407,262**, filed **April 4, 2003**.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

- ☐ The relevance of those listed references which are not in the English language is as follows:
- ☒ There are no listed references which are not in the English language.

Date: August 16, 2004

  
\_\_\_\_\_  
Leslie E. Aberman  
Registration No. 54,836

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BDT-0003	Application No. 10/817,644
		Applicant Brian B. Hashemi	
		Filing Date April 2, 2004	Group 1641
		Confirmation No. 2841	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	1	Black, J.D., et al., "Heterogeneity in lymphocyte spectrin distribution: ultrastructural identification of a new spectrin-rich cytoplasmic structure," <i>J. of Cell Biology</i> , <b>1988</b> , 106, 97-109	
	2	Boxer, L.A., et al., "Neutrophil actin dysfunction and abnormal neutrophil behavior," <i>New England J. of Medicine</i> , <b>1974</b> , 291(21), 1093-1099	
	3	Bunnell, S.C., et al., "Dynamic actin polymerization drives T cell receptor-induced spreading: a role for the signal transduction adaptor LAT," <i>Immunity</i> , <b>2001</b> , 14, 315-329	
	4	Chen, W.-Y., et al., "Direct measurement of neutrophil F-actin content in microvolume whole blood samples," <i>Int. Arch Allergy Immunol.</i> , <b>1996</b> , 110, 325-331	
	5	Egger, G., et al., "A simple method for measuring the F-actin content of human polymorphonuclear leukocytes in whole blood," <i>Virchows Arch</i> , <b>2001</b> , 438, 394-397	
	6	Engelich, G., et al., "Acquired disorders of phagocyte function complicating medical and surgical illnesses," <i>Clinical Infectious Diseases</i> , <b>2001</b> , 33, 2040-2048	
	7	Goebel, J., et al., "Attenuation of IL-2 receptor signaling by CD4-ligation requires polymerized cytoskeletal actin but not P56LCK," <i>Transplant Proc.</i> , <b>1999</b> , 3, 822-824	
	8	Gómez, J., et al., "Physical association and functional relationship between protein kinase C $\zeta$ and the actin cytoskeleton," <i>Eur. J. Immunol.</i> , <b>1995</b> , 25, 2673-2678	
	9	Hashemi, B.B., et al., "T cell activation responses are differentially regulated during clinorotation and in spaceflight," <i>FASEB J.</i> , <b>1999</b> , 13, 2071-2082	
	10	Hashemi, B.B., et al., "Differential regulation of T-cell activation responses in microgravity culture," <i>ASCB Abstract</i> , <b>1997</b> , 1 page	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. BDT-0003		Application No. 10/817,644
	Applicant Brian B. Hashemi		
	Filing Date April 2, 2004		Group 1641
	Confirmation No. 2841		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	11	Krishan, A., "Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining," <i>J. of Cell Biology</i> , <b>1975</b> , 66, 188-193	
	12	Lee, J.K., et al., "Activation induces a rapid reorganization of spectrin in lymphocytes," <i>Cell</i> , <b>1988</b> , 55, 807-816	
	13	Mineshita, M., et al., "Whole-blood incubation method to study neutrophil cytoskeletal dynamics," <i>J. of Immunol. Methods</i> , <b>1997</b> , 202, 59-66	
	14	Naik, N., et al., "Differences in the microtubule organization between normal and CML granulocytes after stimulation with chemotactic peptide," <i>Cell Biol. International</i> , <b>2000</b> , 24(3), 135-144	
	15	Packman, C.H., et al., "Activation of neutrophils: measurement of actin conformational changes by flow cytometry," <i>Blood Cells</i> , <b>1990</b> , 16, 193-207	
	16	Pardi, R., et al., "Antigen-receptor complex stimulation triggers protein kinase C-dependent CD11a/CD18-cytoskeleton association in T lymphocytes," <i>J. of Cell Biology</i> , <b>1992</b> , 116(5), 1211-1220	
	17	Phatak, P.D., et al., "Engagement of the T-cell antigen receptor by anti-CD3 monoclonal antibody causes a rapid increase in lymphocyte F-actin," <i>J. of Cellular Phys.</i> , <b>1994</b> , 159, 365-370	
	18	Pillar, J.D., et al., "A facile, reproducible, species-independent whole blood procedure for measuring leukocyte actin polymerization response to hemoattractants," Abstract of a meeting presentation, <i>ISAC XXI International Congress</i> , May 4-9, <b>2002</b> , 1 page	
	19	Rozdzial, M.M., et al., "Tyrosine-phosphorylated T cell receptor $\zeta$ chain associates with the actin cytoskeleton upon activation of mature T lymphocytes," <i>Immunity</i> , <b>1995</b> , 3, 623-633	
	20	Ryser, J.-E., et al., "The area of attachment of cytotoxic T lymphocytes to their target cells shows high motility and polarization of actin, but not myosin," <i>J. of Immunology</i> , <b>1982</b> , 128(3), 1159-1162	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. BDT-0003	Application No. 10/817,644
		Applicant Brian B. Hashemi	
		Filing Date April 2, 2004	Group 1641
		Confirmation No. 2841	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>21</b>	Tabor, B., et al., "Dialysis neutropenia: the role of the cytoskeleton," <i>Kidney International</i> , <b>1998</b> , 53, 783-789	
	<b>22</b>	Valitutti, S., et al., "Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton," <i>J. Exp. Med.</i> , <b>1995</b> , 181, 577-584	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
BDT-0003

Application No.  
10/817,644

Applicant  
Brian B. Hashemi

Filing Date  
April 2, 2004

Group  
1641

Confirmation No.  
2841

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	23	4,387,088	06/07/83	Barak, et al.	424	3

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO

**EXAMINER****DATE CONSIDERED**